The 8th EURL-AR Proficiency Testing enterococci, staphylococci and E. coli 2010 by Migura, Lourdes Garcia et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
The 8th EURL-AR Proficiency Testing enterococci, staphylococci and E. coli 2010
Migura, Lourdes Garcia; Hendriksen, Rene S.; Karlsmose Pedersen, Susanne; Aarestrup, Frank Møller
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Migura, L. G., Hendriksen, R. S., Karlsmose, S., & Aarestrup, F. M. (2011). The 8th EURL-AR Proficiency
Testing enterococci, staphylococci and E. coli 2010. (1 ed.) Kgs. Lyngby: DTU Food.
The 8th EURL-AR Proficiency Testing
enterococci, staphylococci and E. coli 2010
Lourdes Garcia-Migura
Rene Hendriksen
Susanne Karlsmose
Frank Aarestrup
European Union Reference Laboratory – Antimicrobial Resistance 
 
THE 8th 
Enteroccoci, Staphylococci and E. coli 2010 
EURL-AR Profiency Testing 
 
 
1. edition, June  2011 
Copyright: National Food  Institute, Technical University of Denmark 
Photo: Mikkel Adsbøl 
ISBN: 978-87-92763-05-1 
 
The report is available at 
www.food.dtu.dk 
 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204 
DK-2800 Lyngby 
    
 
 
    
 
 
 
1. INTRODUCTION   ................................................................................................................... 3
2. MATERIALS AND METHODS   ........................................................................................... 4
2.1 Participants in EQAS 2010  ........................................................................................... 4
2.2 Strains   ............................................................................................................................ 5
2.3 Antimicrobials   ............................................................................................................... 5
2.4 Distribution   .................................................................................................................... 6
2.5 Procedure   ....................................................................................................................... 6
3. RESULTS   ................................................................................................................................ 7
3.1 EQAS 2010 versus previous EQASes   .......................................................................... 7
3.2 Deviations by species and method   ............................................................................... 7
3.2.1 Enterococcal trial   ................................................................................................................................... 8
3.2.2 Staphylococcal trial   .............................................................................................................................. 11
3.2.3 E. coli trial   ........................................................................................................................................... 13
3.3 Deviations by laboratories   .......................................................................................... 16
3.3.1 Enterococcal trial   ................................................................................................................................. 16
3.3.2 Staphylococcal trial   .............................................................................................................................. 18
3.3.3 E. coli trial   ........................................................................................................................................... 19
3.4 Deviations by reference strains   .................................................................................. 21
3.4.1 Enterococci   .......................................................................................................................................... 21
3.4.2 Staphylococci   ....................................................................................................................................... 21
3.4.3 E. coli   ................................................................................................................................................... 23
4. DISCUSSION   ........................................................................................................................ 24
4.1 General overview   .................................................................................................................................... 24
4.2 Enterococcal trial   .................................................................................................................................... 25
4.2 Staphylococcal trial   ................................................................................................................................. 25
4.3 E. coli trial   .............................................................................................................................................. 26
5. CONCLUSIONS   ................................................................................................................... 27
6. REFERENCES   ...................................................................................................................... 28
 
    
 
 
 3 
1. INTRODUCTION 
This report summarises the results of the proficiency trial in antimicrobial susceptibility testing 
(AST) also known as External Quality Assurance System (EQAS 2010) concerning Escherichia 
coli, enterococci and staphylococci. The National Food Institute (DTU Food) was appointed as the 
European Union Reference Laboratory on Antimicrobial Resistance (EURL-AR) by the European 
Commission (EC) in 2006. Since then, this has been the 8th
The data in this report are presented with laboratory codes. A laboratory code is known to the 
individual laboratory, whereas the entire list of laboratories and their codes is confidential and 
known only to the EURL-AR and the EU Commission. All conclusions are public. 
 EQAS trial carried out on AST within 
the EURL-AR network. The objective was to monitor the quality of the antimicrobial susceptibility 
data produced by the National Reference Laboratories (NRL) and to identify areas of interest and/or 
laboratories, which may need guidance or assistance to produce reliable susceptibility data.  
The technical advisory group for the EURL-AR EQAS scheme consists of competent 
representatives from all NRL’s, who meet once a year at the EURL-AR workshop. During the 
previous EURL-AR workshops the network agreed upon setting the accepted deviation level for 
laboratory performance to 5%. As in previous EQASes, incorrect results under a 75% threshold for 
a test strain/antimicrobial combination have been further analysed in this report, and if no reason 
was observed that could explain the deviations, the results were subtracted from the evaluation 
report. Two different MIC tests have been performed at DTU-FOOD in all the selected EQAS 
strains followed by verification of the obtained MIC results at the United States Food and Drug 
Administration (FDA), Centre for Veterinary Medicine. Finally, a fourth MIC test was carried out 
at DTU-FOOD after preparing the agar stab cultures to confirm that the final vials contained the 
correct strains with the expected MIC values.  
Firstly, it is important to stress that the results evaluated in this report are the interpretations of the 
AST values. As stated in the protocol, the “main objective of this EQAS is to assess and improve 
the comparability of surveillance and antimicrobial susceptibility data reported to EFSA by the 
different NRLs”, since the AST data that the Member States (MS) report to EFSA is based on 
the interpretation of the results, makes sense for the EQAS to evaluate this interpretation. 
Secondly, the participants of an EQAS should evaluate their own results and introduce 
corrective actions if necessary. The categorization of an uploaded interpretation as incorrect in the 
EURL-AR EQAS should in particular cause the participant to perform a self-evaluation. This self-
evaluation could very well include a comment on the fact that the MIC value for strain 
frequently varies by one dilution either way, in some cases affecting the interpretation of the 
result. Even though, the incorrect interpretation based on this dilution difference will still be 
regarded as a deviation for the overall EQAS reporting, evaluation and in the database, for the self-
evaluation, this comment could be an argument to defend the obtained result internally.  
The EURL-AR is accredited by DANAK as provider of proficiency testing; working with zoonotic 
pathogens and indicator organisms as bacterial isolates (identification, serotyping and antimicrobial 
susceptibility testing).  
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2. MATERIALS AND METHODS  
2.1 Participants in EQAS 2010 
In May 2010, a pre-notification to announce the EQAS 2010 on susceptibility testing for 
enterococci, staphylococci and E. coli was distributed by e-mail to the 32 European NRLs for 
antimicrobial resistance designated by the MS (App. 1). Seven additional laboratories from Spain, 
Romania, Denmark, Switzerland, Norway, Serbia and Iceland were enrolled by the EURL-AR to 
make up a total of 39 participating laboratories, although results from these laboratories have not 
been included in this report. Participants represented all EU countries except for Luxembourg (App. 
2). One of the three NRLs from Spain and the NRL from Romania declined to participate, therefore 
out of 32 participating laboratories, a total of 30 submitted results (Figure 1). Of those, 22, 28 and 
29 laboratories analysed the enterococci, staphylococci and the E. coli strains, respectively. Similar 
number of participation compared to EQAS 2009 when 23, 27 and 28 laboratories submitted results 
for enterococci, staphylococci and E. coli, respectively.  
Figure 1. European map illustrating the participating countries in this EQAS trial 2010. 
 
 
 
      Participants in 
EQAS 2010 
      EU countries not 
participating 
    
 
 
 5 
2.2 Strains  
Eight strains of enterococci, staphylococci and E. coli, respectively, were selected among the DTU 
Food strain collection. The selection of strains was based on antimicrobial resistance profiles and 
their MIC values. For quality assurance purposes, three internal control strains have been repeatedly 
included in every EQAS performed to date, one for each of the bacterial species tested. 
Antimicrobial susceptibility testing of the strains was performed at DTU Food and the MIC values 
obtained were used as reference for the EQAS trial (App. 3). In addition, the results obtained were 
verified by the FDA. After this twofold verification the strains were inoculated in agar stab cultures 
and subsequently sent to the participating laboratories.  
New participating laboratories were provided with the following reference strains, E. faecalis 
ATCC 29212, S. aureus ATCC 25923, S. aureus ATCC 29213 and E. coli ATCC 25922. 
Furthermore, they were requested to save and maintain the ATCC reference strains for quality 
assurance purposes and future EQAS trials. 
 
2.3 Antimicrobials  
The panels of antimicrobials used for AST are listed in Table 1. 
 
Table 1. Panel of antimicrobials used for susceptibility testing in each of the organisms examined  
in the EQAS 2010. 
Enterococcal trial Staphylococcal trial* E. coli trial 
Ampicillin Cefoxitin † Ampicillin† 
Chloramphenicol Chloramphenicol  † Cefotaxime† 
Ciprofloxacin  Ciprofloxacin Ceftazidime 
Erythromycin Erythromycin † Ceftiofur 
Gentamicin Florfenicol † Chloramphenicol† 
Linezolid Gentamicin † Ciprofloxacin† 
Streptomycin Penicillin † Florfenicol 
Quinupristin-dalfopristin Streptomycin † Gentamicin† 
Tetracycline Sulfonamides † Nalidixic acid† 
Vancomycin Tetracycline † Streptomycin† 
 Trimethoprim Sulphonamides† 
  Tetracycline† 
  Trimethoprim† 
†
*No specific recommendations have been suggested by EFSA for monitoring resistance in staphylococci. 
Antimicrobials recommended by EFSA for monitoring European antimicrobial resistance.  
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AST guidelines were set according to the Clinical and Laboratory Standards Institute (CLSI) 
document – M7-A8 (2009) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically; Approved Standard - Eighth Edition”. MIC determination including 
extended spectrum β-lactamase (ESBL) was performed at the EURL-AR using the Sensititre system 
from Trek Diagnostic Systems, Magallan Bioscience. The MIC results were interpreted using the 
epidemiological cut-off values set by EUCAST (www.eucast.org), recommended by EFSA and 
described in the protocol (App. 4). This year results of the ESBL detection were interpreted 
according to the recommendations from the EUCAST expert rules.  
During the previous years, NRL participants at the EURL-AR workshop have agreed upon 
harmonising AST analyses by MIC determination using the antimicrobial panel and 
epidemiological cut-off values recommended by EFSA. 
 
2.4 Distribution  
The protocols and other relevant material were made available to all participants from the EURL-
AR website (http://www.eurl-ar.eu). In June, cultures were dispatched in double pack containers 
(class UN 6.2) to the participating laboratories according to the International Air Transport 
Association (IATA) regulations as UN3373, biological substances category B. 
 
2.5 Procedure  
Upon arrival and prior to performing the antimicrobial susceptibility test, the laboratories were 
instructed to store the tubes in a refrigerator and subculture the strains in accordance with the 
protocol. The cut-off values for the MIC determination were also listed in this protocol (App. 4, 
Tables 3.3.1; 3.3.2 and 3.3.3). Participants using disk diffusion method were advised to interpret the 
results according to their individual breakpoints (App. 5). In both cases the results were categorized 
as resistant or susceptible. The EURL-AR recommended interpreting intermediate results as 
susceptible.  
The EURL-AR is aware that there are two different types of interpretative criteria of results, clinical 
breakpoints and epidemiological cut-off values. The terms ‘susceptible’, ‘intermediate’ and 
‘resistant’ should be reserved for classifications made in relation to the therapeutic application of 
antimicrobial agents. When reporting data using epidemiological cut-off values, bacteria should be 
reported as ‘wild-type’ or ‘non-wild-type’ (Schwarz et al., 2010). Due to the different methods of 
AST used by the participants and also to simplify the interpretation of results, throughout this 
report, we will still maintain the terms susceptible and resistant, even in the cases where we are 
referring to wild-type and non-wild-type strains.  
The laboratories also entered the zone diameter in millimeters or MIC value of the reference strains. 
The results were individually compared to the quality control ranges according to the CLSI 
documents M31-A3 (2008) / M100-S20 (2010), Trek Diagnostic Sensititre System (App. 6).  
All participating laboratories were advised to enter the results into an electronic record sheet at the 
EURL-AR web based database through a secured individual login and password. Alternatively, they 
were allowed to send the record sheet from the enclosed protocol by fax, mail or email to EURL-
AR. The website was opened for data entry until the 15th of September 2010.  
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After submitting the data to the secured web site, the laboratories were instructed to retrieve an 
instantly generated individual report evaluating the submitted results where all deviations from the 
expected interpretations were reported. In addition and with the aim to improve future EQAS trials, 
participants were encouraged to fill in an evaluation report generated from the EURL-AR database. 
 
3. RESULTS 
3.1 EQAS 2010 versus previous EQASes 
Regarding the enterococcal and the staphylococcal trial, the percentages of deviation have been 
constantly decreasing over the four-year period from 8.6% to 2.9% and from 4.2% to 1.2% 
respectively (Figure 2). On the other hand, results from the E. coli trial showed a slight increase in 
the deviation percentage from 1.5% obtained during 2009 to 2.3% in the present year. As illustrated 
in Figure 2, the internal control strains have also followed the increased in deviation, being 
especially high for the Staphylococcus internal control strain.  
 
Figure 2. Comparison of results between previous EQASes and the EQAS 2010 illustrating the deviation levels 
for the different species tested.  
 
 
3.2 Deviations by species and method 
When analysing the data, agar dilution methods and MIC determination have been evaluated 
together. They are both quantitative methods and the obtained values are the concentrations at 
which the antimicrobials inhibit the growth of the microorganisms. On the other hand, the ROSCO 
method used for AST has been considered a disk diffusion (DD) method, since the antimicrobial 
would diffuse in the agar in the same way as from a disk.  
Analysing deviating results by the different species tested (Figure 3), enterococci were the 
organisms producing the highest percentage of deviation when compared to the other two species. 
However, the total deviation percentage for the three species remained lower than 3%. In general, 
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participants performing disk diffusion methods for AST were the ones to contribute with a higher 
percentage of deviations to the final outcome, while participants performing MIC produced higher 
number of correct results. This difference in performance is highly noticeable in the enterococcal 
iteration, where laboratories performing DD have a percentage of deviation fourteen times higher 
than those performing MIC methods.  
A retrospective analysis of the methods used by participants from 2007 to 2010 showed that the 
number of participants performing MIC has increased from 15 to 18, 14 to 21 and 15 to 25 for the 
enterococcal, staphylococcal and E. coli trials, respectively. In the same order, the number of 
laboratories performing disk diffusion has declined from 11 to 4, 17 to 7 and 15 to 4.  
Figure 3. Percentage of deviations for the different strains in comparison with the different methods used for AST. 
 
 
As illustrated in Table 2, the percentage of correct results per strain ranged from 94.5% to 99.6% 
depending of strain. ENT.4,8 was the strains with the lowest percentage of correct results. The 
staphylococcal trial was the most successful.  
The following sections of this report describe in detail the deviations obtained for each one of the 
three species in this EQAS carried out in 2010 depending on strain, antimicrobial and laboratory. 
This report also analyses the results obtained for the quality control reference strains. 
 
3.2.1 Enterococcal trial 
In agreement with previous EURL-AR EQAS’s, when the percentage of correct results of a 
strain/antimicrobial combination was lower than 75%, the data should be further analysed and 
possible subtracted from the main analysis. The percentage of correct results for the combination of 
strain ENT.4,6 with ampicillin was below this threshold, therefore results have been excluded from 
the evaluation. In this particular case, the expected MIC (8 mg/L, resistant) and the cut-off value (> 
4 mg/L) to determine if the strain was resistant were within one fold dilution difference. Figure 4 
shows the distribution of the different MIC values together with the interpretation of these values 
obtained by participants performing MIC for the combination of strain ENT.4,6/ampicillin, where  
0
2
4
6
8
10
12
14
Enterococci Staphylococci E. coli
Pe
rc
en
ta
ge
 o
f d
ev
ia
tio
n
MIC
DD
Total deviation
    
 
 
 9 
Table 2. The number of AST performed and the percentage of correct results for each strain.  
Test 
strain 
AST in 
total 
% 
correct 
Test 
strain 
AST in 
total 
% 
correct 
Test 
strain 
AST in 
total 
% 
correct 
ENT.4,1 200 97.5 ST.4,1 257 97.7 EC.4,1 343 97.1 
ENT.4,2 197 96.9 ST.4,2 230 98.7 EC.4,2 342 99.4 
ENT.4,3 198 97 ST.4,3 258 98.8 EC.4,3 343 98.5 
ENT.4,4 197 98.5 ST.4,4 257 99.2 EC.4,4 344 98 
ENT.4,5 199 96.5 ST.4,5 231 98.7 EC.4,5 342 98.8 
ENT.4,6 180 98.9 ST.4,6 258 99.6 EC.4,6 315 96.5 
ENT.4,7 200 97 ST.4,7 258 98.8 EC.4,7 343 96.2 
ENT.4,8 199 94.5 ST.4,8 257 99.2 EC.4,8 319 97.2 
 
12 participants obtained MIC 4 mg/L, whereas three and one obtained 8 mg/L and 16 mg/L, 
respectively. Results from four participants performing disk diffusion have been excluded from this 
particular analysis. However, in Appendix 7a the total percentage of positive results for each strain 
and antimicrobial tested is presented. 
Figure 4. Distribution of the different MIC values obtained by participants performing MIC for the combination 
ENT.4,6/ampicillin. 
 
As illustrated in Figure 5, strain ENT.4,8 exhibited the highest deviations in terms of total deviation 
with a value of 5.5%. In agreement with the results obtained in previous years, the highest 
percentage of deviation was observed for laboratories performing disk diffusion, and significant 
differences were obtained when comparing the two methods (p < 0.01). Out of the 22 laboratories 
taking part in the enterococcal trial, 18 performed MIC methods whereas four conducted disk 
diffusion.  
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Figure 5. Summary of the deviations obtained per strain according to the method used for AST by all participants.  
 
After discussion with the network (workshop of April 2010), the number of antimicrobials tested 
against enterococci was reduced from thirteen to ten. Out of those antimicrobials selected in the 
panel, nine were compounds recommended by EFSA for monitoring antimicrobial resistance across 
the EU. In this EQAS iteration, synacid, gentamicin and ampicillin were the antimicrobials 
presenting the highest percentage of deviation with values of 9.5%, 6.8% and 5% respectively 
(Figure 6). These three antimicrobials belonged to the panel of antimicrobials recommended by 
EFSA. On the other hand, the percentage of deviation for the rest of the antimicrobials remained 
lower than 2.3%.  
Figure 6. Deviations in enterococcal strains per antimicrobial tested. 
 
*Antimicrobials recommended by EFSA for monitoring antimicrobial resistance across the EU. 
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3.2.2 Staphylococcal trial 
Regarding the staphylococcal strains, two combinations strain/antimicrobial produced more than 
25% incorrect results; ST.4,2/ciprofloxacin and ST.4,5/ciprofloxacin. In both cases the expected 
result for this antimicrobial (MIC = 2 mg/L) and the cut-off value (1 mg/L) to categorise the strains 
as resistant were within one fold dilution. Thus, producing results within the correct range (± one 
fold dilution) could conclude in the wrong outcome. These differences in the obtained results 
appeared to be caused by participants using MIC as well as disk diffusion. These data have been 
excluded from the report. Figure 7 shows the distribution of the MIC results obtained by the NRL’s 
for the combinations ST.4,2 with ciprofloxacin. In the analysis, only the interpretation of the MIC 
results reported by the participants performing MIC has been included. The combination 
ST.4,5/ciprofloxacin is not illustrated in a figure since only two different values were reported, 
eleven NRL’s obtained MIC 1 mg/L and interpreted this value as susceptible against ten NRL’s that 
obtained MIC 2 mg/L and interpreted the result as resistant.  
Figure 7. Distribution of the different MIC values obtained by participants performing MIC for the combination 
ST.4,2/ciprofloxacin. 
 
All strains presented deviations lower than 2.3% (Figure 8). Out of 28 laboratories involved in the 
staphylococcal trial, 21 used MIC methods by comparison to the 16 from the previous year. In 
addition, five participants performed disk diffusion instead of seven from last year, and two instead 
of one performed the ROSCO method. Contrarily to results obtained in previous EQAS, no 
significant differences were observed in results obtained by the two different AST methods (p = 
0.9). 
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Figure 8. Summary of the deviations obtained per strain according to the method used for AST by all participants. 
Results produced by MIC and agar dilution have been evaluated together whereas disk diffusion (DD) has been 
evaluated together with ROSCO method.  
 
Deviations for all of the drugs were really low and remained below 3% (Figure 9). To see the 
results generated in the staphylococcal trial with respect to each one of the antimicrobials tested, 
please refer to appendix 7b. 
Figure 9. Deviations in staphylococcal strains per antimicrobial tested. 
 
Methicillin resistant strains. 
Among the eight staphylococcal strains selected for the trial, ST.4,1, ST.4,4 and ST.4,5 were 
confirmed to be methicillin resistant. As it was agreed in the EURL-AR workshop held in 
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participant #39 has not reported any results for this part of the test. On the other hand, the rest of the 
participants performed a total of 211 tests for confirmation of mecA in the eight strains with a 100% 
successful rate.  
3.2.3 E. coli trial 
Regarding the analysis of the E. coli data, results obtained for the two combinations of 
strain/antimicrobial EC.4,6/streptomycin and EC.4,8/florfenicol were lower than 75% with values 
of 60% and 61.5%, respectively. In both cases, the expected MIC (= 32 mg/L) was one fold dilution 
above the epidemiological cut-off value (16 mg/L). Results from these combinations have been 
excluded from the analysis. Figure 10 and Figure 11 show the distribution of the MIC and the 
interpretation of the values obtained by the NRL’s. The interpretations of the millimetres diameters 
obtained by three participants performing disk diffusion have not been included in any of the two 
analyses. 
Figure 10. Distribution of the different MIC values obtained by participants performing MIC for the combination 
EC.4,6/streptomycin. 
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Figure 11. Distribution of the different MIC values obtained by participants performing MIC for the combination 
EC.4,8/florfenicol. 
 
The deviation values in terms of total deviation ranged between 0.6% and 3.8% depending on the 
tested strain (Figure 12), with EC.4,7 obtaining the highest deviation percentage (3.8%). 
Figure 12. Summary of the deviations obtained per strain according to the method used for AST by all 
participants.  
 
However, laboratories performing disk diffusion achieved a significantly higher percentage of 
deviation than those participants using MIC methods (p < 0.01). Furthermore, for strains EC.4,6 and 
E.C.4,7 the deviations obtained by laboratories using disk diffusion were four times higher than 
those obtained by participants performing MIC. This year, the E. coli trial was performed by 29 
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laboratories of which 25 conducted MIC determination and four disk diffusion. For more details in 
all deviations per antimicrobial, please refer to Appendix 7c. 
Figure 13 represents the deviation obtained for each antimicrobial tested. Ceftiofur (XNL) and 
florfenicol (FFN) were the antimicrobials which have created more difficulties for the NRL’s. 
However, the deviation level for the antimicrobials recommended by EFSA for monitoring 
antimicrobial resistance remained lower than 3%. For the first time, the deviation obtained for 
ciprofloxacin was really low (1.7%) resulting in a great improvement when compared with results 
from previous years. Strains EC.4,4, EC.4,6 and EC.4,8 exhibited low level of resistance to 
ciprofloxacin with values of 0.5 mg/L, 0.5 mg/L and 0.25 mg/L, respectively. Deviations in these 
strains were mainly caused by laboratory #40 performing disk diffusion that categorised those 
strains as susceptible instead of resistant (cut-off value for ciprofloxacin is 0.032 mg/L). 
Figure 13. Deviations in E. coli strains per antimicrobial tested. 
 
*Antimicrobials recommended by EFSA for monitoring antimicrobial resistance across the EU. 
Extended spectrum betalactamase (ESBL) producing strains 
Following the EUCAST experts rules, in this year’s EQAS for cefotaxime (CTX), ceftazidime 
(CAZ) and ceftiofur (XNL), MIC values and interpretation for these antimicrobials should be 
reported as found. The highest deviation was obtained for ceftiofur, with a value of 9.6% mainly 
caused by participant #39 performing MIC. This participant produced six out of eight results 
incorrectly without a plausible explanation.  
Out of the eight E. coli strains selected for the EQAS 2010, EC.4,5 and EC.4,8 were “true ESBL’s” 
and harboured blaCTX-M-1 and blaCTX-M-15 genes, respectively. In addition, EC,4.7 yielded the 
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and did not take part in these mandatory tests. For the rest of the participants, nine out of 28 
obtained deviations when confirming extended spectrum betalactamase production.  
Laboratories #2 and #32 failed to identify the strain EC.4,8 as ESBL producer. Laboratory #32 
obtained MIC values ≤ 0.12 mg/L and ≤ 0.25 mg/L for cefotaxime and ceftazidime, respectively 
instead of 4 mg/L and 32 mg/L, therefore confirmatory tests were never performed. In the case of 
laboratory #2, the antimicrobials listed in their panel to test against E. coli only contained one 
cephalosporin; cefotaxime. Laboratory #2 obtained a MIC of 0.12 mg/L instead of 4 mg/L and 
although the participant performed the two confirmatory tests on the strain, both of them were 
negative for ESBL production.  
However, laboratory #2 has contacted the EURL-AR regarding the ESBL results for EC.4,8. This 
NRL intended to use the EQAS strains to evaluate their Vitek system, they tested EC.4,8 in parallel 
with Vitek and disk diffusion and they obtained exactly the same results: CTX ≤ 1mg/l, CAZ ≤ 
1mg/L, cefepim ≤ 1mg/L, gentamicin ≤ 1mg/L by Vitek and CTX 33mm, CAZ 28mm, gentamicin 
20mm by disk diffusion. After obtaining the EQAS evaluation, they went back to the frozen vial 
sent by the EURL-AR and they performed MIC testing which revealed the following MIC values: 
CTX 128 mg/L (resistant) and gentamicin >32mg/L (resistant). Since blaCTX-M-15 
A total of seven participants obtained deviations when dealing with the ampC strain EC.4,7. Three 
laboratories, #15, #22 and #32 confirmed this strain to be ESBL producer together with ampC. The 
three laboratories reported results for cefoxitin in agreement with the expected MIC (> 16 mg/L or 
< 14 mm), and therefore they identified EC.4,7 as ampC. For some unknown reason, participant 
#15 did not perform confirmatory test for ESBL but still identified EC,4.7 as ESBL producer. On 
the other hand, laboratory #22 obtained an increase in the diameters (≥ 5mm) when performing the 
two confirmatory tests (CAZ:CAZ/CL and CTX:CTX/CL) and reported the strain as ESBL 
producer. Participant #32 also reported an increase in the MIC ratio but only for one of the 
confirmatory test (CAZ/CL:CAZ). Finally, the remaining four participants did not confirm EC.4,7 
as an AmpC positive strain. Participants #24 and #30 obtained the correct results for all tests 
(cefoxitin and the two confirmatory tests) but failed to interpret the results correctly. Participant #29 
obtained a susceptible value for cefoxitin and did not find synergy when performing the 
confirmatory test (CTX/CL:CTX). Participant #40 reported EC.4,7 as susceptible for the two 
cephalosporins tested; therefore they did not suspect this strain to be cephalosporin resistant. In 
addition, participant #44 identified strain EC.4,1 as an ampC. They obtained MICs of 1 mg/L, 2 
mg/L and >16 mg/L for ceftazidime, cefotaxime and cefoxitin, respectively and they did not find 
synergy in one of the ESBL confirmatory tests (CAZ/CL:CAZ). 
is generally 
plasmid mediated, a possible explanation for these results may be the lost of the plasmid harbouring 
the CTX gene together with an amonoglycoside modifying enzyme during processing of the strain. 
However, further studies should be carried out to clarify this issue.  
 
3.3 Deviations by laboratories  
3.3.1 Enterococcal trial 
When analysing laboratory performance to only those antimicrobials reported to EFSA, out of the 
22 participating laboratories, five obtained deviations greater than 5% acceptance limit (Figure 10). 
This number decreased to four when including all antimicrobials tested. The percentage of 
deviations differed widely between the laboratories, with a maximum of 23.9% and a minimum of 
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0% (Figure 14). Three out of the four laboratories performing disk diffusion obtained deviation 
greater than the 5% threshold. For laboratory #26 the deviations appeared to be caused mainly by 
three antimicrobials, chloramphenicol, gentamicin and synacid. All susceptible strains were 
reported as resistant. Laboratory #40 seemed to have difficulties testing against ampicillin, 
gentamicin and linezolid and also reported most of the susceptible strains as resistant. Participant 
#18 deviated in gentamicin and synacid with the same issue, reporting of susceptible strains as 
resistant strains. Finally, participant #39 failed to produce correct results in five different 
antimicrobials and in all cases they reported all resistant strains as susceptible. 
 
Figure 14. Individual deviations per laboratory in percentage of their total number of enterococcal tests. The 
laboratories were ranked by decreasing percentage of deviations in accordance with deviations obtained in 
antimicrobials recommended by EFSA.  
 
*Laboratories performing DD for AST 
As shown in Figure 15, a total of 17 laboratories out of the 22 taking part in the enterococcal trial, 
achieved the acceptance level of performance lower than 5%. On the other hand, five of the 
participants obtained deviations higher than the agreed threshold. One of these participants fell in 
the interval of deviation between 21% and 25% and therefore was identified as outlier. However, 
Appendix 8a summarises all deviations per laboratory. 
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Figure 15. The number of laboratories listed in intervals of percent of total deviations in antimicrobials 
recommended by EFSA. The vertical line marks the acceptance limit set by the EURL-AR at 5%.  
  
3.3.2 Staphylococcal trial  
In this EQAS staphylococcal trial, two laboratories exceeded the 5% acceptance limit of deviation 
(Figure 16). Furthermore, 16 laboratories performed 100% correctly. Deviations for participant #39 
were mainly caused for trimethoprim. In three occasions they obtained resistant values instead of 
susceptible. Laboratory #21 performing MIC for AST has obtained susceptible values for penicillin 
instead of resistant values. Appendix 8b shows in detail the deviations per laboratory. 
 
Figure 16. Individual deviations per laboratory in percentage of their total number of staphylococcal tests. The 
laboratories were ranked by decreasing percentage of deviations. 
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When clustering the laboratories in intervals of deviation as illustrated in Figure 17, the majority of 
the laboratories clustered in the intervals between 0% and 1% deviations. No outliers were 
identified in this staphylococcal trial, but the participant that did not perform confirmation of mecA 
cassette will be contacted by the EURL-AR in the near future. 
Figure 17. The number of laboratories listed in intervals of percent of total deviations. The vertical line marks the 
5% acceptance limit set by the EURL-AR. 
  
3.3.3 E. coli trial 
Analysis of results based only on those antimicrobials recommended by EFSA (Figure 18) showed 
that out of the 29 participating laboratories, two obtained deviations above the stipulated 5%. For 
laboratory #39, with the highest deviation in this trial, the 21.9% deviation was caused by six 
different antimicrobials, cefotaxime, chloramphenicol, gentamicin, sulfamethoxazole, tetracycline 
and trimethoprim. For participant #40, the deviations were caused mainly by two antimicrobials, 
ceftazidime and ciprofloxacin. In addition, when analysing results including all the antimicrobials 
tested instead of just those recommended by EFSA, the deviation percentage of laboratory #39 
increased considerably from 21.9% to 30.8%.  
A total of 18 laboratories obtained 100% of correct results in the antimicrobials reported to EFSA, 
whereas when including all antimicrobials in the panel, the number of participants performing 
100% decrease to 16. To see the deviations for each individual laboratory, please refer to Appendix 
8c. 
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Figure 18. Individual deviations per laboratory in percentage of their total number of E. coli tests. The laboratories 
were ranked by decreasing percentage of deviations in accordance with deviations obtained in antimicrobials 
recommended by EFSA. 
 
*Laboratories performing DD for AST 
As illustrated in Figure 19, the majority of the laboratories obtained deviations in the interval 
between 0% and 1%. Only two laboratories clustered outside the 5% threshold. For this E. coli trial, 
only one participant was identified as outlier. Appendix 8 is a summary of all the deviations 
obtained per participating laboratory.  
Figure 19. The number of laboratories listed in intervals of percent of total deviations. The vertical line marks the 
5% acceptance limit set by the EURL-AR. 
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3.4 Deviations by reference strains  
As the majority of the participants performing AST by disk diffusion methods have followed CLSI 
guidelines, the results for the reference strains have been evaluated according to them (the quality 
control ranges can be found in Appendix 6).  
3.4.1 Enterococci 
The 17 participating laboratories that carried out MIC determination in the reference strain E. 
faecalis ATCC 29212 obtained 100% of results within range (Table 3). This is a total of 152 correct 
tests.  
As CLSI has not published a QC range for E. faecalis ATCC 29212 using disk diffusion, the three 
laboratories that have entered data for the reference strain performing this method for AST could 
not be evaluated.  
Table 3. Deviations obtained for the reference strain E. faecalis ATCC 29212 by  
MIC determination and the minimum and maximum values reported for each antimicrobial.  
E. faecalis ATCC 29212 
Antimicrobial MIC deviations  /Total no. of tests  QC range MIC 
Min 
 value 
Max 
 value 
Ampicillin  0/16 0.5 - 2 0.5 2 
Chloramphenicol 0/16 4 - 16 4 8 
Ciprofloxacin 0/12 0.25 - 2 0.5 2 
Erythromycin 0/17 1 - 4 1 4 
Gentamicin 0/17 4 - 16 4 ≤128 
Linezolid 0/14 1 - 4 1 2 
Streptomycin 0/17 0-256 32 128 
Synacid 0/9 2 - 8 4 8 
Tetracycline 0/17 8 - 32 8 32 
Vancomycin 0/17 1 - 4 2 4 
 
3.4.2 Staphylococci 
A total of five laboratories performed disk diffusion within the reference strain S. aureus ATCC 
25923. Table 4 shows the results and the deviations obtained per antimicrobial. Only two of the 
values, one for cefoxitin and one for gentamicin were out of range when compared to the expected 
results. The total number of tests performed with this reference strain was 45 of which 43 were in 
range. 
In addition, two participant performed ROSCO method within this reference strain and the results 
have not been included in Table 4, since the quality control values were different to those used for 
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disk diffusion. One of the participants exhibited a deviation for chloramphenicol tested against S. 
aureus ATCC 25923. These participants performed a total of 15 tests and 14 were correct. 
Table 4. Deviations obtained for the reference strain S. aureus ATCC 25923 by disk diffusion. 
Antimicrobial Deviation/Total  no. of tests  QC range 
Min  
value 
Max 
 value  
Cefoxitin 1/5 23-29 26 32 
Chloramphenicol 0/3 16-26 18 26 
Ciprofloxacin 0/5 22-30 23 29 
Erythromycin 0/5 22-30 22 28.5 
Florfenicol 0/3 None 20 29 
Gentamicin 1/5 19-27 19 30 
Penicillin 0/5 26-37 30 37 
Streptomycin 0/4 14-22 14 22 
Sulfisoxazole 0/3 24-30 24 30 
Tetracycline 0/4 24-34 24 33 
Trimethoprim 0/3 19-26 20 26 
 
The 20 laboratories which tested the reference strain S. aureus ATCC 25913 conducting MIC and 
agar dilution methods produced three deviations for chloramphenicol and trimethoprim. This means 
a total of 169 correct results out of 172 tests performed within this strain (Table 5). 
Table 5. Range of obtained values for S. aureus ATCC 25913 by MIC determination. 
Antimicrobial Deviation/Total  no. of tests  QC range 
Min  
value 
Max 
 value  
Cefoxitin 0/13 1-4 2 4 
Chloramphenicol 2/18 2-8 4 16 
Ciprofloxacin 0/17 0.12-0.5 0.12 0.5 
Erythromycin 0/20 0.25-1 0.25 1 
Florfenicol 0/9 2-8 4 8 
Gentamicin 0/19 0.12-1 0.25 ≤2 
Penicillin 0/18 0.25-2 0.25 2 
Sulfisoxazole 0/8 32-128 32 128 
Tetracycline 0/20 0.12-1 0.5  
Trimethoprim 1/15 1-4 0.5 4 
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3.4.3 E. coli 
Four laboratories carried out disk diffusion methods with the reference strain E. coli ATCC 25922. 
The total number of test performed with this strain was 48, of these, eight were out of range (Table 
6).  
Table 6. Range of obtained values for the reference strain E. coli ATCC 25922 by disk diffusion and the minimum 
and maximum values reported for each antimicrobial. 
Antimicrobial Deviation/Total  no of tests  QC range 
Min  
value 
Max 
 value  
Ampicillin 0/2 16-22 18 20 
Cefotaxime 1/4 29-35 32 40 
Cefoxitin 1/3 23-29 25 30 
Ceftazidime 1/3 25-32 27 33 
Ceftiofur 1/3 26-31 27 33 
Chloramphenicol 1/3 21-27 22 28 
Ciprofloxacin 0/4 30-40 34 40 
Florfenicol 1/2 22-28 23 33 
Gentamicin 0/4 19-26 20 24.4 
Imipenem 1/2 26-32 29 40 
Nalidixic acid 0/4 22-28 25 27 
Sulfisoxazole 0/2 15-23 18 23 
Tetracycline 0/3 18-25 20 25 
Trimethoprim 1/4 21-28 17 26 
 
Finally, 25 laboratories tested the reference strain using MIC determination. They performed a total 
of 288 tests of which seven were incorrect causing an average deviation of 2.4%. The deviations of 
this strain were produced by four antimicrobials, ampicillin, cefotaxime, ciprofloxacin and 
gentamicin (Table 7).  
    
 
 
 24 
Table 7. Range of obtained values for the E. coli ATCC 25922 using MIC determination and the minimum and 
maximum values reported for each antimicrobial. 
Antimicrobial Deviation/Total  no of tests QC range 
Min  
value 
Max 
 value  
Ampicillin 1/25 2-8 2 16 
Cefotaxime 3/25 0.03-0.12 0.06 4 
Cefoxitin 0/6 2-8 2 4 
Ceftazidime 0/20 0.06-0.5 0.12 0.25 
Ceftiofur 0/3 0.25-1 0.25 0.5 
Chloramphenicol 0/24 2-8 4 8 
Ciprofloxacin 2/25 0.004-0.016 0.008 0.03 
Florfenicol 0/21 2-8 4 8 
Gentamicin 1/25 0.25-1 0.25 2 
Imipenem 0/4 0.06-0.25 0.12 0.25 
Nalidixic acid 0/24 1-4 1 4 
Streptomycin 0/23 4-16 4 8 
Sulfisoxazole 0/17 8-32 16  
Tetracycline 0/24 0.5-2 1 2 
Trimethoprim 0/22 0.5-2 0.5 1 
 
4. DISCUSSION 
4.1 General overview  
Analysing the deviating results for each one of the species tested (Figure 2), we can observe a 
decrease in the percentage of deviation for the enterococci and staphylococci EQAS during the last 
four years, reaching in the EQAS 2010 the lowest percentage of deviations. On the other hand, 
when looking at the E. coli trial, the percentage of deviation has slightly increased after 2009, when 
the results reached the lowest percentage of deviations after a gradual decrease. Furthermore, as 
illustrated in Figure 2, deviations obtained in the internal control strains for all species have also 
increased in this EQAS 2010. However, results from Figure 2 should be interpreted with care, since 
the number of NRL’s participating during the years continues to change and the difficulty of the test 
strains is believed to be increasing over the years. There are still two NRL’s that have declined to 
participate in all enterococci, staphylococci and E. coli EQAS conducted to date. 
The EURL-AR has worked towards harmonizing methodology between NRL’s and has 
recommended MIC as the gold standard method for AST. In this EQAS trial, a considerable 
increase in the number of participants performing MIC methods has been observed when compared 
to previous years, especially for the staphylococci iteration. Also for both species, enterococci and 
E. coli, laboratories performing disk diffusion obtained significantly higher percentage of deviation 
    
 
 
 25 
when compare to participants performing MIC; therefore, the EURL-AR encourage participants 
using disk diffusion to harmonise methods towards those that deliver a better quality of results, in 
the case of these two species, MIC. 
4.2 Enterococcal trial 
Deviations in the eight enterococci strains varied between 5.5% and 1% depending on strain, and 
were mainly generated by participants performing disk diffusion for AST rather than MIC. 
Furthermore, three out of the four laboratories performing disk diffusion obtained deviations higher 
than the 5% acceptance limit.  
Synacid was the antimicrobial exhibiting the highest deviation percentage followed by gentamicin 
and ampicillin. As these three antimicrobials are recommended by EFSA, the importance of these 
deviations is slightly higher than those that are not used for the EFSA report.  
For synacid, deviations were mainly caused by two participants performing disk diffusion; these 
were participants #26 and #18. In both cases, they obtained resistant values when the strains were 
expected to be susceptible. Furthermore, laboratory #26 produced the high percentage of deviating 
results achieved against gentamicin. This participant obtained resistance values in the six strains 
that were susceptible.  
Overall, it appears that the causes of the deviations are individual NRL’s conducting disk diffusion 
and having encountered some type of methodological problem. When performing this method for 
AST, it is important to consider the different factors that may influence the results, such as 
temperature, age and concentration of the antimicrobial disks, volume, moisture and pH of the agar 
media in the petri dish and the turbidity and density of the inoculum.  
The number of laboratories deviating more than the 5% acceptance limit was five, one less than in 
the previous EQAS 2009. Of those, one participant clustered in the interval between 20%-25% 
deviation and was considered an outlier. This participant and the one that obtained a 12.7% 
deviation will be contacted by the EURL-AR in the near future with the aim to identify possible 
causes of deviations and improve the quality of their results.  
This year, the number of laboratories performing 100% correctly has increased to 13 from nine in 
2009. In addition, for the first time, the total deviation for the enterococcal trial falls below 4%. 
Also MIC determination of the quality control strain E. faecalis ATCC 29212 showed a total of 
100% correct results in all antimicrobials tested. This is a total of 152 correct results. The analysis 
of the reference strains was used as a quality assessment to monitor the excellence of the laboratory 
procedures. 
4.2 Staphylococcal trial 
Contrarily to what has been observed in previous years when participants performing disk diffusion 
reported significantly better results than those performing MIC, for the first time in this 
staphylococci iteration, no significant differences were observed between the two AST methods. 
Furthermore, the number of participants performing MIC has increased from 16 in 2009 to 21 this 
year, demonstrating a successful implementation of the new method for AST. All of the strains and 
antimicrobials tested presented deviations below 2.3%.  
With regards to detection of methicillin resistance, as in previous years, only participant #39 did not 
perform the relevant tests to identify potential methicillin resistant staphylococci strains that may 
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have been included in the EQAS. This participant will be contacted by the EURL-AR to clarify any 
particular reasons for why this test has never been performed. The rest of the NRLs have conducted 
a total of 211 correct tests. These results demonstrate that all laboratories within the network have 
the tools optimized to correctly identify MRSA, and show the quality of the data reported 
throughout the EU. 
Two laboratories clustered outside the 5% limit and most of the participants grouped in the 
deviation interval between 0% and 1%. No outliers were identified in this staphylococcal iteration.  
Few deviations were obtained in the reference strains for both, laboratories performing disk 
diffusion on strain S. aureus ATCC 25923 and laboratories using MIC methods on strain S. aureus 
ATCC 25913. One participant obtained a deviation when testing S. aureus ATCC 25923 against 
cefoxitin. This type of deviation is of high importance, since may induce to identify a particular 
strain as methicillin resistant. Those laboratories obtaining deviations in the reference strains are 
recommended to take action and assess possible factors that may have a negative influence on the 
quality of the results.  
4.3 E. coli trial 
In the present EQAS, participants have obtained slightly higher percentage of deviations than in the 
previous years’ EQASes. High deviation percentages were obtained in three of the antimicrobials 
tested against E. coli strains. However, none of these were antimicrobials recommended by EFSA 
for monitoring antimicrobial resistance. Deviations in EFSA recommended antimicrobials remained 
lower than 3% which is a very positive outcome. Having into consideration that three of the test 
strains exhibited low level resistance to ciprofloxacin, deviations for this antimicrobial were very 
low which is a great improvement from previous years’ results. This is probably due to both, the 
decrease in the number of laboratories performing disk diffusion and the use of a low concentration 
of ciprofloxacin (1 µg) in the disks that increases the sensitivity of the assay.  
Two laboratories obtained deviations above the 5% acceptance limit and one of them clustered in 
the interval between 20%-25% deviation. This participant appeared to have difficulties in six 
different antimicrobials without a particular pattern. However, the results for the reference strains 
were all correct. This participant has been identified as an outlier and will be contacted by the 
EURL-AR with the aim to assist in any practicality which may need improvement. For the rest of 
the participants, they majority clustered in the interval of deviation between 0% and 1% which is a 
very positive result.  
Regarding the reference strain E. coli ATCC 25922, the percentage of results within range for all 
tests performed by disk diffusion was 83.3%, much lower than results obtained by participants 
performing MIC determination (97.6%). All participants obtaining deviations in the reference strain 
should revise their methods and also assess if contamination of the reference strain has occurred.  
Extended spectrum betalactamase (ESBL) 
With regard to cephalosporin antimicrobials including the new ESBL interpretation stated in the 
protocol, the percentage of deviation for cefotaxime (CTX) and ceftazidime (CAZ) has decreased 
from previous years.  
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Two of the EQAS strains (EC.4,5 and EC.4,8) exhibited resistance to cephalosporins and were 
confirmed to be “true ESBL strains”. Two laboratories failed to identify some of these strains, one 
of them used only one cephalosporin in the panel of antimicrobials to test against E. coli. The 
EURL-AR recommends the use of at least two cephalosporin antimicrobials to help identifying 
ESBL strains, since they can exhibit susceptibility to some cephalosporins and resistance to others. 
Still, the two confirmatory tests are crucial tools for final identification of ESBL and should be 
performed with care. Since the combination disk is a similar procedure to disk diffusion, the same 
factors should be taken into consideration; those are age and concentration of the antimicrobials in 
the disks, pH of the media, moisture and volume of the agar and finally density of the inoculum 
together with good laboratory practice when spreading the bacteria in the petri dish.  
For strain EC.4,7 (ampC), seven participants produced deviations in this strain; an extremely high 
number of participants failing to obtained the correct identification, considering the importance of 
these type of resistance. As stated in the protocol, “ampC detection can be performed by testing the 
microorganism to cefoxitin and resistance could indicate ampC.” In addition, even though 
identification of betalactamase production is a mandatory part of the EQAS, one of the participants 
did not participate.  
In all, these ten laboratories are encouraged to revise their procedures for ESBL identification and 
confirmation, and ensure the implementation of a better detection system. 
 
5. CONCLUSIONS 
Although the number of laboratories performing above the 5% acceptance limit remained low 
compared to previous years, two outliers have been identified, one for enterococci trial and one for 
the E. coli trial. Since one of the aims of the EURL-AR is to give specific recommendations to 
target the individual difficulties, these participants will be contacted in the near future to assess the 
causes of the deviations and provide guidelines to improve the results. On the same line, laboratory 
#39, that has never performed the MRSA and ESBL confirmatory tests, will also be contacted in an 
attempt to help them establish the methodology to perform these type of analysis. 
There is still a significant difference in the quality of results obtained by participants performing 
MIC when compared to those performing disk diffusion, especially for the enterococcal and the E. 
coli trials. The EURL-AR still encourages participants to harmonize towards MIC methods for 
AST, since they appear to be more reliable and reproducible. 
Regarding ESBL producing E. coli, they are still considered a priority area for the EURL-AR. For 
the last two years the number of laboratories failing to identify the strains resistant to 
cephalosporins has been remarkably high, especially for the ampC strain. We encourage NRL’s 
obtaining deviating results in these strains to perform a re-test as a training exercise and contact us 
in case of any doubts in the interpretation of results.  
Finally, the EURL-AR is open to any suggestions to make a better forthcoming EQAS and 
encourage the entire network to bring forward any ideas regarding training courses, improvements 
and areas for discussion that can expand our knowledge in antimicrobial resistance. 
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EURL-AR EQAS pre-notification:  
EQAS 2010 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI  
The EURL are pleased to announce the launch of another EQAS. The EQAS provides the 
opportunity for proficiency testing, which is considered an important tool for the production of 
reliable laboratory results of consistently good quality. 
This EQAS offers antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci 
and eight enterococci isolates. Additionally, new participants will be offered the following QC 
strains: E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), S. aureus ATCC 
25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) (for MIC). 
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, you do not need to sign 
up to be a participant. All who receive this pre-notification are automatically regarded as 
participants. 
Participation is free of charge for all NRL’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the EQAS coordinator with documents or other information that can 
ease the parcel’s way through customs (eg. specific text that should be written on the invoice). As 
means of avoiding passing the deadline, we ask you to send us this information already at this stage. 
For your information, the content of the parcel is “Biological Substance Category B”: Eight E. coli, 
eight staphylococci, eight enterococci and for new participants also the QC strains mentioned 
above. The strains are expected to arrive at your laboratory in June 2010. 
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2010. The protocol will be 
provided by e-mail/available on the website (www.crl-ar.eu). 
 
Returning of results: Results must be returned to the National Food Institute by the 1st September 
2010. When you enter your results via a password-protected website, an evaluation report of your 
results will be generated immediately.  
 
EQAS report: When the EQAS is concluded, the data will be collected in an overall report in which 
it is possible to see all participants’ results in comparison. In the report the laboratories will be 
coded, which ensures full anonymity; only the National Food Institute and the EU Commission will 
be given access to un-coded results. 
 
Next EQAS: The next EURL EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter which will be carried out in October 2010. 
 
Any comments regarding the EQAS, please contact me by e-mail (lgmi@food.dtu.dk) or by 
fax (+45 3588 6341). 
Sincerely, 
Lourdes Garcia Migura 
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Ent. Staph. E.coli Institute Country
X X X Austrian Agency for Health and Food Safety Austria
X X Institute of Public Health Belgium
X X X NRL AR on food, National Diagnostic and Research Veterinary Institute Bulgaria
X Veterinary Services Cyprus
X X X State Veterinary Institute Prague Czech Republic
X X X The National Food Institute, Copenhagen Denmark
X X X DTU Veterinærinstituttet, Aarhus Denmark
X X X Estonian Veterinary and Food Laboratory Estonia
X X X Finnish Food Safety Authority EVIRA Finland
X ANSES - Maisons-Alfort Laboratory for Food Safety France
X X ANSES - Ploufragan/Plouzané Laboratory France
X X X ANSES - Lyon Laboratory France
X X ANSES - Fougères Laboratory France
X X X Federal Institute for Risk Assessment Germany
X X X Veterinary Laboratory of Chalkis Greece
X X X Central Agricultural Office, Veterinary Diagnostical Directorate Hungary
X X X University of Iceland Iceland
X X X Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X X National Diagnostic Centre of Food and Veterinary Service Latvia
X X X National Veterinary Laboratory Lithuania
X X X Public Health Laboratory Malta/UK
X X X Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X X Veterinærinstituttet Norway
X X X National Veterinary Research Institute Poland
X X X Laboratorio National de Investigacáo Veterinaria Portugal
*Institute for Hygiene and Veterinary Public Health Romania
X X X National Institute of Research-Development for Microbiology and Immunology “Cantacuzino” 
Romania
X X X Institute of Veterinary Medicine of Serbia Serbia
X X X State Veterinary and Food Institute  (SVFI) Slovakia 
X X National Veterinary Institute Slovenia
X Laboratorio Central de Sanidad Animal de Santa Fe Spain
X Laboratorio Central de Sanidad Animal de Algete Spain
*C N de Alimentacion. Agencia Espanola de Seguridad Alimentria y Spain 
X X X Complutense University of Madrid Spain
X X X National Veterinary Institute, SVA Sweden
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Enterococci test strains and reference values (MIC)
Strain Species AMP CHL CIP ERY GEN LZD STR SYN TET VAN
ENT.4,1 E. faecium 4 8 4 >32 ≤16 2 >2048 8 >32 ≤1
ENT.4,2 E. faecalis ≤2 ≤4 2 >32 512 1 >2048 16 >32 ≤1
ENT.4,3 E. faecalis ≤2 >64 1 >32 ≤16 1 >2048 8 >32 2
ENT.4,4 E. faecalis ≤2 >64 1 >32 512 1 >2048 16 >32 4
ENT.4,5 E. faecalis ≤2 4 2 1 ≤16 1 ≤64 8 ≤1 2
ENT.4,6 E. faecium 8 8 1 >32 ≤16 2 >2048 8 >32 ≤1
ENT.4,7 E. faecium 4 8 1 >32 ≤16 2 >2048 4 >32 ≤1
ENT.4,8 E. faecium 4 4 1 2 32 2 ≤64 4 >32 >32
Strain Species AMP CHL CIP ERY GEN LZD STR SYN TET VAN
ENT.4,1 E. faecium S S S R S S R R R S
ENT.4,2 E. faecalis S S S R R S R S R S
ENT.4,3 E. faecalis S R S R S S R S R S
ENT.4,4 E. faecalis S R S R R S R S R S
ENT.4,5 E. faecalis S S S S S S S S S S
ENT.4,6 E. faecium R S S R S S R R R S
ENT.4,7 E. faecium S S S R S S R R R S
ENT.4,8 E. faecium S S S S S S S R R R
AMP:ampicillin GEN: gentamicin SYN:synacid
CHL: chloramphenicol KAN: kanamycin TET: tetracycline
CIP: ciprofloxacin LZD: linezolid VAN: vancomycin
ERY: erythromycin STR: streptomycin
Resistant
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Staphylococci test strains and reference values (MIC)
Strain mecA CHL CIP ERY FFN FOX GEN MRS PEN STR SMX TET TMP
ST.4,1 yes 8 0.5 >16 4 8 0.5 yes 8 >64 ≤32 >32 ≤0.5
ST.4,2 8 2 >16 4 4 1 2 16 ≤32 >32 ≤0.5
ST.4,3 8 0.5 0.5 4 4 >16 8 8 ≤32 ≤0.5 >32
ST.4,4 yes 8 0.5 0.5 4 16 ≤0.25 yes 8 >64 ≤32 >32 >32
ST.4,5 yes 4 2 ≤0.25 4 8 >16 yes >16 >64 512 32 ≤0.5
ST.4,6 8 0.5 0.5 4 4 0.5 2 >64 ≤32 >32 >32
ST.4,7 8 0.5 ≤0.25 4 2 0.5 ≤0.06 ≤4 ≤32 ≤0.5 ≤0.5
ST.4,8 8 1 0.5 4 4 0.5 4 ≤4 64 >32 >32
Strain CHL CIP ERY FFN FOX GEN MRS PEN STR SMX TET TMP
ST.4,1 S. aureus S S R S R S yes R R S R S
ST.4,2 S. aureus S R R S S S S R S S R S
ST.4,3 S. aureus S S S S S R S R S S S R
ST.4,4 S. aureus S S S S R S yes R R S R R
ST.4,5 S. aureus S R S S R R yes R R R R S
ST.4,6 S. aureus S S S S S S S R R S R R
ST.4,7 S. aureus S S S S S S S S S S S S
ST.4,8 S. aureus S S S S S S S R S S R R
CHL: chloramphenicol PEN: penicillin
CIP: ciprofloxacin STR: streptomycin
ERY: erythromycin SMX: Sulphamethoxazole
FFN: florfenicol TET: tetracyclin
GEN: gentamicin TMP: trimethoprim
MRS: methicillin resistant
Resistant
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E. coli  test strains and reference values (MIC)
Strain AMP CAZ CHL CIP CTX ESBL gene FFN FOX GEN NAL SMX STR TET TMP XNL CAZ/CLV CTX/CLV
EC.4,1 >32 0.25 >64 0.03 ≤0.120 >64 1 ≤4 >1024 128 ≤2 ≤1 ≤0.5
EC.4,2 2 0.25 4 ≤0.015 ≤0.120 4 ≤0.5 ≤4 ≤64 ≤8 ≤2 ≤1 ≤0.5
EC.4,3 >32 0.25 4 ≤0.015 ≤0.120 4 2 ≤4 >1024 >128 >32 >32 ≤0.5
EC.4,4 >32 0.25 8 0.5 ≤0.120 8 ≤0.5 >64 >1024 128 >32 ≤1 ≤0.5
EC.4,5 >32 2 4 ≤0.015 >4 bla CTX-M-1 4 4 ≤0.5 ≤4 ≤64 ≤8 ≤2 ≤1 >8 synergy synergy
EC.4,6 >32 0.125 >64 0.5 ≤0.120 16 4 16 >1024 32 >32 >32 ≤0.5
EC.4,7 >32 16 4 0.25 >4 bla CMY-2 4 64 1 >64 >1024 128 >32 ≤1 8
EC.4,8 >32 32 >64 >4 >4 bla CTX-M-15 32 8 >16 >64 >1024 >128 >32 >32 >8 synergy synergy
Strain AMP CAZ CHL CIP CTX ESBL gene FFN FOX GEN NAL SMX STR TET TMP XNL CAZ/CLV CTX/CLV
EC.4,1 R S R S S R S S S R R S S S
EC.4,2 S S S S S S S S S S S S S S
EC.4,3 R S S S S S S S S R R R R S
EC.4,4 R S S R S S S S R R R R S S
EC.4,5 R R S S R bla CTX-M-1 S S S S S S S S R synergy synergy
EC.4,6 R S R R S S S S S R R R R S
EC.4,7 R R S R R bla CMY-2 S R S R R R R S R
EC.4,8 R R R R R bla CTX-M-15 R S R R R R R R R synergy synergy
AMP: ampicillin CTX: cefotaxime STR: streptomycin *Synergy when CAZ/CLV and CTX/CLV ≥ 8 
CAZ: ceftazidime FFN: florphenicol SMX: sulfamethoxazole Resistant
CHL: chloramphenicol FOX: cefoxitin TET: tetracycline
XNL: ceftiofur GEN: gentamicin TMP: trimethoprim
CIP: ciprofloxacin, NAL: nalidixic acid CLV: clavulanic acid
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1 INTRODUCTION 
One of the tasks as the EU Reference Laboratory for Antimicrobial Resistance is to organise and 
conduct an External Quality Assurance System (EQAS) on susceptibility testing of E. coli, 
enterococci and staphylococci. The EC/Ent/Staph EQAS 2010 will include susceptibility testing of 
eight E. coli, eight enterococci and eight staphylococci strains together with susceptibility testing of 
the reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), S. 
aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) (for 
MIC).  
For new participants of the EQAS who have not already received the mentioned reference strains, 
these are included in the parcel. The reference strains will not be included in the years to come. The 
reference strains are original certified cultures and are free of charge. Please take proper care of the 
strains. Handle and maintain them as suggested in the manual ‘Subculture and Maintenance of QC 
Strains’. Please use them for future internal quality control for susceptibility testing in your 
laboratory.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
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The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
E. coli, enterococci and staphylococci. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by different laboratories on E. 
coli, enterococci and staphylococci and to harmonise the breakpoints used within the EU. 
3 OUTLINE OF THE EQAS 2010 
3.1 Shipping, receipt and storage of strains 
In June 2010, the EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight E. coli, eight enterococci and eight staphylococci strains. 
Reference strains will be included for participants who have not previously received these. All 
strains are non-toxin producing human pathogens Class II. There might be ESBL-producing strains 
and MRSA among the selected material. The reference strains are shipped lyophilised, and the test 
strains are stab cultures. On arrival, the stab cultures must be subcultured, and all cultures should be 
kept refrigerated until testing. A suggested procedure for reconstitution of the lyophilised reference 
strains is presented below.  
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please see the document ‘Instructions for opening and reviving lyophilised cultures’ on the EURL-
AR-website (see www.eurl-ar.eu). 
3.3 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the following 
antimicrobials by the method used in the laboratory when performing monitoring for EFSA. For 
MIC, the cut off values listed in tables 3.3.1; 3.3.2 and 3.3.3 should be used. The epidemiological 
cut-off values allow two categories of characterisation – resistant or sensitive. Participants using 
disk diffusion are recommended to interpret the results according to their individual breakpoints, 
categorising them into the terms resistant and sensitive. A categorization as intermediary is not 
accepted; therefore intermediary results should be interpreted as susceptible. Interpretations in 
concordance with the expected value will be categorised as ‘correct’, whereas interpretations that 
deviate from the expected interpretation will be categorised as ‘incorrect’.  
The cut-off values used in the interpretation of the MIC results are developed by EUCAST 
(www.eucast.org). Participants performing disk diffusion, please notice that EUCAST has 
recommended epidemiological cut-off values for interpretation of inhibition zones for some of the 
antimicrobials. 
With regard to MIC range and/or disc content we ask you to fill in these pieces of information in 
the database. Also, if you do not use the cut-off values listed in the protocol for interpretation of the 
susceptibility results, please fill in or update the breakpoints used, in the database. 
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3.3.1 E. coli  
Antimicrobials for E. coli MIC (g/mL) R is > 
Ampicillin, AMP 8 
Cefotaxime, CTX 0.25  
Ceftazidime, CAZ 0.5  
Ceftiofur, XNL 1 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.032  
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Nalidixic acid, NAL 16 
Streptomycin, STR 16 
Sulfonamides, SMX 256 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
 
ESBL production 
The following tests regarding ESBL production are mandatory: All strains resistant against 
cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) should be confirmed by confirmatory 
tests for ESBL production. 
The confirmatory tests for ESBL production require testing with a pure antimicrobial (CTX and 
CAZ) vs. a test with the same antimicrobial combined with a -lactamase inhibitor (clavulanic 
acid). Synergy is defined as a 3 dilution steps difference between the two compounds in at least one 
of the two cases (MIC ratio  8, E-test 3 dilution steps) or an increase in zone diameter  5 mm 
(CLSI M100 Table 2A; enterobacteriaceae). If the test shows signs of synergy it is an indication of 
the presence of ESBL.  
Confirmatory tests for Metallo beta lactamase require comparison between imipenem (IMI) and 
IMI/EDTA, synergy is in this test defined as a MIC ratio  8 or E-test 3 dilution steps difference 
(CLSI M100 Table 2A; enterobacteriaceae). If the test shows signs of synergy it is an indication of 
the presence of ESBL.  
Additionally, AmpC detection can be performed by testing the microorganism to cefoxitin (FOX), 
resistance to FOX could indicate AmpC. Verification of AmpC requires PCR or sequencing. 
The EURL-AR aim to harmonize with EUCAST expert rules. CONCERNING CEFOTAXIME, 
CEFTAZIDIME AND/OR CEFTIOFUR USED WHEN DETECTING ESBL-PRODUCING 
STRAINS IN THIS EQAS, MIC VALUES AND INTERPRETATIONS FOR THESE 
ANTIMICROBIALS SHOULD BE REPORTED AS FOUND.  
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3.3.2 Enterococci  
Antimicrobials for enterococci MIC (g/mL)R is > 
MIC (g/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Streptomycin, STR 128 512 
Quinpristin-dalfopristin (Synacid), SYN 1 32 
Tetracycline, TET 4 4 
Vancomycin, VAN 4 4 
 
Please find information on the test forms showing which test strains are E. faecium and E. faecalis 
respectively.  
 
3.3.3 Staphylococci  
Antimicrobials for S. aureus MIC (g/mL)R is > 
Cefoxitin 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 2 
Penicillin, PEN 0.125 
Streptomycin, STR 16 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 2 
 
Some of the strains may be methicillin resistant. Testing the staphylococci also include tests 
regarding methicillin resistance - confirmation of mecA presence is mandatory. The strains may 
be tested by any method that you prefer. The result must be uploaded as ‘positive’ or ‘negative’. 
According to the CLSI recommendations (M100-S19, table 2C), all MRSA should be regarded 
resistant for all β-lactam antibiotics. 
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4 REPORTING OF RESULTS AND EVALUATION 
Fill in your results in the test forms, and enter your results into the interactive web database. Please 
read the detailed description below before entering your results. When you enter the results via the 
web, you will be guided through all steps on the screen and you will immediately be able to view 
and print an evaluation report of your results. Please submit results by latest September, 30, 2010.  
If you do not have access to the Internet, or if you experience difficulties entering the data, please 
return results by e-mail, fax or mail to the National Food Institute.  
All results will be summarized in a report which will be made available to all participants. The data 
in the report will be presented with laboratory codes. A laboratory code is known to the individual 
laboratory, whereas the entire list of laboratories and their codes is confidential and known only to 
the EURL-AR and the EU Commission. All conclusions are public. 
If you have any questions, please do not hesitate to contact: 
Lourdes Migura 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6284 
Fax: +45 3588 6341 
E-mail: lgmi@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read this passage before entering the web page. Before you go ahead, you need your test 
form by your side together with your breakpoint values.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS 2010 start web page (http://thor.dfvf.dk/crl) then write your 
username and password in low cases and press enter. Your username and password is the same as in 
the previous EQAS’s arranged by The National Food Institute. If you have problems with the login 
please contact us.  
Click on either “E. coli test results”, “enterococci test results” or “staphylococci test results” 
depending on your results. The below description is aimed at Salmonella entry but is exactly the 
same as for E. coli, enterococci and staphylococci entry. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
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In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the susceptibility testing of Salmonella and the brand 
of discs, tablets, MIC trays etc.  
Fill in the relevant information, either disk content or MIC range. If you use disk diffusion, please 
upload the breakpoints used. 
Click on "save and go to next page”  
In the data entry pages for each E. coli, enterococci and staphylococci strain, you enter the obtained 
value and the interpretation as R or S. 
For E. coli, you also type in results for the ESBL tests. 
If you have not used an antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. If you do not use CLSI 
guidelines for AST on the reference strains, please add a comment on the method used. 
Click on "save and go to next page" 
This page is a menu, from where you can review the input pages, approve your input and finally see 
and print the evaluated results: 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
Please fill in the evaluation form. 
Approve your input. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.  
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Breakpoints used in daily routine (disk diffusion) - Enterococci
Antimicrobial Lab. no. R≤ mm S≥ mm
Ampicillin, AMP 15 16 19
18 16 17
26 16 17
40 16 17
Chloramphenicol, CHL 15 19 23
18 12 18
23 12 18
26 12 18
40 12 18
Ciprofloxacin, CIP 18 15 21
26 15 21
40 15 21
Erythromycin, ERY 15 17 22
18 13 23
26 13 23
40 13 23
Gentamicin, GEN 15 11 17
18 12 15
40 12 15
Linezolid, LZD 15 24 24
18 20 23
26 20 23
40 20 23
Streptomycin, STR 15 12 14
18 11 12
40 11 15
Tetracycline, TET 15 17 19
18 14 19
26 14 19
40 14 16
Vancomycin, VAN 15 17 17
18 14 17
26 14 17
40 14 17
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Breakpoints used in daily routine (disk diffusion) - Staphylococci
Antimicrobial Lab. no. R ≤ mm S ≥ mm
Chloramphenicol, CHL 14 22 23
15 19 22
18 12 18
29 12 18
40 12 18
Ciprofloxacin, CIP 13 15 21
14 18 22
15 19 22
18 15 21
40 15 21
Erythromycin, ERY 13 16 22
14 18 22
15 17 22
18 13 23
40 13 23
Florfenicol, FFN 14 18 22
15 14 19
18 12 18
Gentamicin, GEN 13 12 15
14 19
15 20 20
18 12 15
40 12 15
Penicillin, PEN 13 28 29
14 29
15 29 29
18 28 29
40 28 29
Streptomycin, STR 13 12 15
15 13 15
18 11 12
40 11 15
Sulfamethoxazole, SMX 13 12 17
14 11 17
18 12 17
40 12 17
Tetracycline, TET 13 14 19
14 20 23
15 17 19
18 14 19
40 14 19
Trimethoprim, TMP 14 15 20
18 10 16
40 10 16
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Breakpoints used in daily routine (disk diffusion) - E. coli
Antimicrobial Lab. no. R ≤ mm S ≥ mm
Ampicillin, AMP 14 19
15 15 21
18 13 17
40 16 17
Cefotaxime, CTX 14 26
15 22 26
18 27
40 14 23
Ceftazidime, CAZ 14 20
15 18 26
18 22
40 14 18
Ceftiofur, XNL 14 21
15 17 21
Chloramphenicol, CHL 14 23
15 18 22
18 12 18
40 12 18
Ciprofloxacin, CIP 15 21 25
18 15 21
40 15 21
Florphenicol, FFN 14 19
15 14 19
18 12 18
Gentamicin, GEN 14 18
15 15 18
18 12 15
40 12 18
Nalidixic acid, NAL 14 20
15 14 20
18 13 19
40 13 19
Streptomycin, STR 15 12 15
18 11 15
40 11 15
Sulfamethoxazole, SMX 14 17
15 11 17
18 12 17
40 12 17
Tetracycline,TET 14 19
15 16 19
18 11 15
40 11 15
Trimethoprim, TMP 14 20
15 11 16
18 10 16
40 10 16
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Antimicrobial MIC
Ampicillin, AMP 0.5 - 2
Chloramphenicol, CHL 4 - 16
Ciprofloxacin, CIP 0.25 - 2
Erythromycin, ERY 1 - 4
Florfenicol, FFN 2 - 8
Gentamicin, GEN 4 - 16
Linezolid, LZD 1 - 4
Synacid, SYN 2 - 8
Tetracycline, TET 8 - 32
Vancomycin, VAN 1 - 4
S. aureus ATCC 29213 
Antimicrobial Disk diffusion ROSCO MIC 
Chloramphenicol, CHL 16 - 26 None 2 - 8
Ciprofloxacin, CIP 22 - 30 21 - 29 0.12 - 0.5
Erythromycin, ERY 22 - 30 26 - 33 0.25 - 1
Florfenicol, FFN None None 2 - 8
Gentamicin, GEN 19 - 27 25 - 32 0.12 - 1
Penicillin, PEN 26 - 37 None 0.25 - 2
Streptomycin, STR 14 - 22 None None
Suphonamides, SMX 24 - 30 26 - 34 32 - 128
Tetracycline, TET 24 - 34 23 - 33 0.12 - 1
Trimethoprim, TMP 19 - 26 19 - 25 1-4
Antimicrobial Disk difusion MIC
Amoxicillin cl., AUG 18 - 24 2 - 8
Ampicillin, AMP 16 - 22 2 - 8
Cefotaxime, CTX 29 - 35 0.03 - 0.12
Ceftazidime, CAZ 25 - 32 0.06 - 0.5
Ceftiofur, XNL 26 - 31 0.25 - 1
Chloramphenicol, CHL 21 - 27 2 - 8
Ciprofloxacin, CIP 30 - 40 0.004 - 0.016
Florphenicol, FFN 22 - 28 2 - 8
Gentamicin, GEN 19 - 26 0.25 - 1
Nalidixic acid, NAL 22 - 28 1 - 4
Streptomycin, STR None 4 - 16
Sulphonamides, SMX 15 - 23 8 - 32
Tetracycline, TET 18 - 25 0.5 - 2
Trimethoprim, TMP 21 - 28 0.5 - 2
MIC ranges and disc diffusion ranges are according to CLSI M100-S19 with one exception: The MIC 
range for streptomycin is according to Sensititre. Additionally, the range for ciprofloxacin is extended 
to include 0.016 as well.
Quality control ranges for the control strains
E. faecalis  ATCC 29212
E. coli  ATCC 25922
S. aureus ATCC 25923
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Percentage of resistant and sensitive enterococci
Strain Antimicrobial
Expected 
result %R %S
Number 
expected 
results
Number 
deviating 
results
EURL ENT.4,1 Ampicillin , AMP S 15 85 17 3
Chloramphenicol, CHL S 5 95 21 1
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 100 0 22 0
Gentamicin, GEN S 5 95 21 1
Linezolid, LZD S 0 100 19 0
Streptomycin, STR R 100 0 22 0
Synacid, SYN R 100 0 11 0
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN S 0 100 22 0
TOTAL 195 5
EURL ENT.4,2 Ampicillin , AMP S 0 100 20 0
Chloramphenicol, CHL S 0 100 22 0
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 95 5 21 1
Gentamicin, GEN R 95 5 21 1
Linezolid, LZD S 0 100 18 0
Streptomycin, STR R 95 5 20 1
Synacid, SYN S 20 80 8 2
Tetracycline, TET R 95 5 21 1
Vancomycin, VAN S 0 100 22 0
TOTAL 191 6
EURL ENT.4,3 Ampicillin , AMP S 0 100 20 0
Chloramphenicol, CHL R 100 0 22 0
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 100 0 22 0
Gentamicin, GEN S 14 86 19 3
Linezolid, LZD S 5 95 18 1
Streptomycin, STR R 100 0 21 0
Synacid, SYN S 20 80 8 2
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN S 0 100 22 0
TOTAL 192 6
EURL ENT.4,4 Ampicillin , AMP S 0 100 20 0
Chloramphenicol, CHL R 100 0 22 0
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 100 0 22 0
Gentamicin, GEN R 100 0 22 0
Linezolid, LZD S 0 100 18 0
Streptomycin, STR R 100 0 21 0
Synacid, SYN S 20 80 8 2
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN S 5 95 21 1
TOTAL 194 3
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Strain Antimicrobial
Expected 
result %R %S
Number 
expected 
results
Number 
deviating 
results
EURL ENT.4,5 Ampicillin , AMP S 0 100 20 0
Chloramphenicol, CHL S 0 100 22 0
Ciprofloxacin , CIP S 11 89 16 2
Erythromycin, ERY S 9 91 20 2
Gentamicin, GEN S 9 91 20 2
Linezolid, LZD S 0 100 19 0
Streptomycin, STR S 5 95 21 1
Synacid, SYN S 20 80 8 2
Tetracycline, TET S 0 100 22 0
Vancomycin, VAN S 0 100 22 0
TOTAL 192 7
EURL ENT.4,6 Ampicillin , AMP R 20 80 4 16
Chloramphenicol, CHL S 5 95 21 1
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 100 0 22 0
Gentamicin, GEN S 5 95 21 1
Linezolid, LZD S 0 100 19 0
Streptomycin, STR R 100 0 22 0
Synacid, SYN R 100 0 11 0
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN S 0 100 22 0
TOTAL 182 18
EURL ENT.4,7 Ampicillin , AMP S 10 90 18 2
Chloramphenicol, CHL S 5 95 21 1
Ciprofloxacin , CIP S 0 100 18 0
Erythromycin, ERY R 100 0 22 0
Gentamicin, GEN S 9 91 20 2
Linezolid, LZD S 5 95 18 1
Streptomycin, STR R 100 0 22 0
Synacid, SYN R 100 0 11 0
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN S 0 100 22 0
TOTAL 194 6
EURL ENT.4,8 Ampicillin , AMP S 10 90 18 2
Chloramphenicol, CHL S 5 95 21 1
Ciprofloxacin , CIP S 6 94 17 1
Erythromycin, ERY S 5 95 21 1
Gentamicin, GEN S 9 91 20 2
Linezolid, LZD S 5 95 18 1
Streptomycin, STR S 10 90 19 2
Synacid, SYN R 100 0 11 0
Tetracycline, TET R 100 0 22 0
Vancomycin, VAN R 95 5 21 1
TOTAL 188 11
Antimicrobials producing deviations
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Percentage of resistant and sensitive staphylococci
Strain Antimicrobial
Expected 
results %R %S
Number 
expected 
results
Number 
deviating 
results
EURL ST.4,1 Cefoxitin, FOX R 95 5 19 1
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 4 96 26 1
Erythromycin, ERY R 96 4 27 1
Florfenicol, FFN S 0 100 15 0
Gentamicin, GEN S 0 100 25 0
Penicillin, PEN R 100 0 25 0
Streptomycin, STR R 100 0 23 0
Sulfamethoxazole, SMX S 6 94 17 1
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP S 9 91 21 2
TOTAL 251 6
EURL ST.4,2 Cefoxitin, FOX S 0 100 20 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP R 56 44 15 12
Erythromycin, ERY R 96 4 27 1
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN S 0 100 26 0
Penicillin, PEN R 96 4 24 1
Streptomycin, STR S 0 100 23 0
Sulfamethoxazole, SMX S 0 100 18 0
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP S 4 96 22 1
TOTAL 242 15
EURL ST.4,3 Cefoxitin, FOX S 0 100 20 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 0 100 27 0
Erythromycin, ERY S 4 96 27 1
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN R 100 0 27 0
Penicillin, PEN R 96 4 24 1
Streptomycin, STR S 4 96 22 1
Sulfamethoxazole, SMX S 0 100 18 0
Tetracycline, TET S 0 100 28 0
Trimethoprim, TMP R 100 0 23 0
TOTAL 255 3
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EURL ST.4,4 Cefoxitin, FOX R 100 0 20 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 0 100 27 0
Erythromycin, ERY S 4 96 27 1
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN S 4 96 25 1
Penicillin, PEN R 100 0 25 0
Streptomycin, STR R 100 0 23 0
Sulfamethoxazole, SMX S 0 100 18 0
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP R 100 0 23 0
TOTAL 255 2
EURL ST.4,5 Cefoxitin, FOX R 100 0 19 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP R 41 59 11 16
Erythromycin, ERY S 0 100 28 0
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN R 100 0 27 0
Penicillin, PEN R 100 0 25 0
Streptomycin, STR R 100 0 23 0
Sulfamethoxazole, SMX R 84 16 16 3
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP S 0 100 23 0
TOTAL 239 19
EURL ST.4,6 Cefoxitin, FOX S 0 100 20 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 0 100 27 0
Erythromycin, ERY S 0 100 28 0
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN S 0 100 26 0
Penicillin, PEN R 96 4 24 1
Streptomycin, STR R 100 0 23 0
Sulfamethoxazole, SMX S 0 100 19 0
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP R 100 0 23 0
TOTAL 257 1
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EURL ST.4,7 Cefoxitin, FOX S 5 95 19 1
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 0 100 27 0
Erythromycin, ERY S 0 100 28 0
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN S 0 100 26 0
Penicillin, PEN S 4 96 24 1
Streptomycin, STR S 0 100 23 0
Sulfamethoxazole, SMX S 0 100 19 0
Tetracycline, TET S 0 100 28 0
Trimethoprim, TMP S 4 96 22 1
TOTAL 255 3
EURL ST.4,8 Cefoxitin, FOX S 0 100 20 0
Chloramphenicol, CHL S 0 100 25 0
Ciprofloxacin, CIP S 4 96 26 1
Erythromycin, ERY S 0 100 28 0
Florfenicol, FFN S 0 100 14 0
Gentamicin, GEN S 0 100 26 0
Penicillin, PEN R 96 4 24 1
Streptomycin, STR S 0 100 23 0
Sulfamethoxazole, SMX S 0 100 18 0
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP R 100 0 23 0
TOTAL 255 2
Antimicrobials producing deviations
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Strain Antimicrobial
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results %R %S
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Number 
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EURL EC.4,1 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX S 7 93 27 2
Ceftazidime, CAZ S 4 96 23 1
Ceftiofur, XNL S 11 89 8 1
Chloramphenicol, CHL R 97 3 28 1
Ciprofloxacin, CIP S 0 100 29 0
Florphenicol, FFN R 100 0 24 0
Gentamicin, GEN S 3 97 28 1
Nalidixic acid, NAL S 0 100 29 0
Streptomycin, STR R 96 4 27 1
Sulfamethoxazole, SMX R 96 4 27 1
Tetracycline, TET S 3 97 28 1
Trimethoprim, TMP S 4 96 26 1
TOTAL 333 10
EURL EC.4,2 Ampicillin, AMP S 0 100 29 0
Cefotaxime, CTX S 0 100 29 0
Ceftazidime, CAZ S 0 100 24 0
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL S 0 100 29 0
Ciprofloxacin, CIP S 0 100 29 0
Florphenicol, FFN S 0 100 24 0
Gentamicin, GEN S 0 100 29 0
Nalidixic acid, NAL S 0 100 29 0
Streptomycin, STR S 0 100 27 0
Sulfamethoxazole, SMX S 4 96 27 1
Tetracycline, TET S 3 97 28 1
Trimethoprim, TMP S 0 100 27 0
TOTAL 340 2
EURL EC.4,3 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX S 0 100 29 0
Ceftazidime, CAZ S 0 100 24 0
Ceftiofur, XNL S 11 89 8 1
Chloramphenicol, CHL S 0 100 29 0
Ciprofloxacin, CIP S 0 100 29 0
Florphenicol, FFN S 4 96 23 1
Gentamicin, GEN S 0 100 29 0
Nalidixic acid, NAL S 0 100 29 0
Streptomycin, STR R 100 0 28 0
Sulfamethoxazole, SMX R 100 0 28 0
Tetracycline, TET R 93 7 27 2
Trimethoprim, TMP R 96 4 26 1
TOTAL 338 5
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EURL EC.4,4 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX S 0 100 29 0
Ceftazidime, CAZ S 0 100 24 0
Ceftiofur, XNL S 10 90 9 1
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin, CIP R 97 3 28 1
Florphenicol, FFN S 4 96 23 1
Gentamicin, GEN S 3 97 28 1
Nalidixic acid, NAL R 100 0 29 0
Streptomycin, STR R 100 0 28 0
Sulfamethoxazole, SMX R 96 4 27 1
Tetracycline, TET R 97 3 28 1
Trimethoprim, TMP S 0 100 27 0
TOTAL 337 7
EURL EC.4,5 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX R 100 0 29 0
Ceftazidime, CAZ R 96 4 23 1
Ceftiofur, XNL R 89 11 8 1
Chloramphenicol, CHL S 3 97 28 1
Ciprofloxacin, CIP S 0 100 29 0
Florphenicol, FFN S 0 100 24 0
Gentamicin, GEN S 0 100 29 0
Nalidixic acid, NAL S 0 100 29 0
Streptomycin, STR S 0 100 27 0
Sulfamethoxazole, SMX S 4 96 27 1
Tetracycline, TET S 0 100 29 0
Trimethoprim, TMP S 0 100 27 0
TOTAL 338 4
EURL EC.4,6 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX S 0 100 29 0
Ceftazidime, CAZ S 0 100 24 0
Ceftiofur, XNL S 11 89 8 1
Chloramphenicol, CHL R 97 3 28 1
Ciprofloxacin, CIP R 97 3 28 1
Florphenicol, FFN S 17 83 20 4
Gentamicin, GEN S 7 93 27 2
Nalidixic acid, NAL S 7 93 27 2
Streptomycin, STR R 58 42 15 11
Sulfamethoxazole, SMX R 100 0 28 0
Tetracycline, TET R 100 0 29 0
Trimethoprim, TMP R 100 0 27 0
TOTAL 319 22
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EURL EC.4,7 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX R 97 3 28 1
Ceftazidime, CAZ R 96 4 23 1
Ceftiofur, XNL R 78 22 7 2
Chloramphenicol, CHL S 7 93 27 2
Ciprofloxacin, CIP R 93 7 27 2
Florphenicol, FFN S 4 96 23 1
Gentamicin, GEN S 0 100 29 0
Nalidixic acid, NAL R 97 3 28 1
Streptomycin, STR R 100 0 28 0
Sulfamethoxazole, SMX R 100 0 28 0
Tetracycline, TET R 100 0 28 0
Trimethoprim, TMP R 100 0 28 0
TOTAL 330 13
EURL EC.4,8 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX R 90 10 26 3
Ceftazidime, CAZ R 92 8 22 2
Ceftiofur, XNL R 100 0 9 0
Chloramphenicol, CHL R 97 3 28 1
Ciprofloxacin, CIP R 100 0 29 0
Florphenicol, FFN R 67 33 16 8
Gentamicin, GEN R 90 10 26 3
Nalidixic acid, NAL R 100 0 29 0
Streptomycin, STR R 100 0 28 0
Sulfamethoxazole, SMX R 100 0 28 0
Tetracycline, TET R 100 0 29 0
Trimethoprim, TMP R 100 0 27 0
TOTAL 326 17
Antimicrobials producing deviations
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Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
15 EURL ENT.4,5 Ciprofloxacin , CIP R 16 S 2 DD
EURL ENT.4,2 Synacid, SYN R 10 S 16
EURL ENT.4,3 Gentamicin, GEN R 11 S 16
EURL ENT.4,3 Synacid, SYN R 12 S 8
EURL ENT.4,4 Synacid, SYN R 11 S 16
EURL ENT.4,5 Gentamicin, GEN R 12 S 16
EURL ENT.4,5 Streptomycin, STR R 6 S 64
EURL ENT.4,5 Synacid, SYN R 13 S 8
19 EURL ENT.4,3 Gentamicin, GEN R 1024 S 16 MIC
20 EURL ENT.4,7 Ampicillin , AMP R 8 S 4 MIC
24 EURL ENT.4,1 Ampicillin , AMP R 8 S 4 MIC
EURL ENT.4,1 Chloramphenicol, CHL R 9 S 8
EURL ENT.4,1 Gentamicin, GEN R 6 S 16
EURL ENT.4,2 Synacid, SYN R 12 S 16
EURL ENT.4,3 Gentamicin, GEN R 10 S 16
EURL ENT.4,3 Synacid, SYN R 12 S 8
EURL ENT.4,4 Synacid, SYN R 13 S 16
EURL ENT.4,5 Ciprofloxacin , CIP R 14 S 2
EURL ENT.4,5 Gentamicin, GEN R 9 S 16
EURL ENT.4,5 Synacid, SYN R 13 S 8
EURL ENT.4,6 Chloramphenicol, CHL R 9 S 8
EURL ENT.4,6 Gentamicin, GEN R 6 S 16
EURL ENT.4,7 Chloramphenicol, CHL R 10 S 8
EURL ENT.4,7 Gentamicin, GEN R 6 S 16
EURL ENT.4,8 Chloramphenicol, CHL R 10 S 4
EURL ENT.4,8 Erythromycin, ERY R 6 S 2
EURL ENT.4,8 Gentamicin, GEN R 6 S 32
EURL ENT.4,8 Streptomycin, STR R 6 S 64
EURL ENT.4,8 Vancomycin, VAN S 16 R >32
34 EURL ENT.4,4 Vancomycin, VAN R 8 S 4 MIC
EURL ENT.4,1 Ampicillin , AMP R 8 S 4
EURL ENT.4,7 Ampicillin , AMP R 8 S 4
EURL ENT.4,8 Ampicillin , AMP R 16 S 4
EURL ENT.4,2 Erythromycin, ERY S <0.5 R >32
EURL ENT.4,2 Gentamicin, GEN S <2 R 512
EURL ENT.4,2 Streptomycin, STR S <8 R >2048
EURL ENT.4,2 Tetracycline, TET S <0.5 R >32
EURL ENT.4,1 Ampicillin , AMP R 10 S 4
EURL ENT.4,3 Linezolid, LZD R 20 S 1
EURL ENT.4,7 Gentamicin, GEN R 12 S 16
EURL ENT.4,7 Linezolid, LZD R 17 S 2
EURL ENT.4,8 Ampicillin , AMP R 6 S 4
EURL ENT.4,8 Ciprofloxacin , CIP R 12 S 1
EURL ENT.4,8 Gentamicin, GEN R 6 S 32
EURL ENT.4,8 Linezolid, LZD R 16 S 2
EURL ENT.4,8 Streptomycin, STR R 8 S 64
44 EURL ENT.4,6 Ampicillin , AMP S 4 R 8 MIC
DD
MIC
18 DD
26 DD
39 MIC
37
40
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Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
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interpretation
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MIC
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EURL ST.4,1 Erythromycin, ERY S 13 R >16
EURL ST.4,2 Erythromycin, ERY S 14 R >16
EURL ST.4,5 Sulfamethoxazole, SMX S 12 R 512
EURL ST.4,1 Ciprofloxacin, CIP R 21 S 0,5
EURL ST.4,8 Ciprofloxacin, CIP R 21 S 1
EURL ST.4,2 Penicillin, PEN S 0.5 R 2
EURL ST.4,3 Penicillin, PEN S 2 R 8
EURL ST.4,6 Penicillin, PEN S 1 R 2
EURL ST.4,8 Penicillin, PEN S 0.5 R 4
22 EURL ST.4,3 Erythromycin, ERY R 2 S 0,5 MIC
23 EURL ST.4,1 Cefoxitin, FOX S 4 R 8 MIC
24 EURL ST.4,3 Streptomycin, STR R <8 S 8 MIC
EURL ST.4,1 Sulfamethoxazole, SMX R 256 S 32
EURL ST.4,1 Trimethoprim, TMP R 4 S 0,5
EURL ST.4,4 Erythromycin, ERY R >4 S 0,5
EURL ST.4,5 Sulfamethoxazole, SMX S 128 R 512
33 EURL ST.4,7 Cefoxitin, FOX R 8 S 2 MIC
34 EURL ST.4,5 Sulfamethoxazole, SMX S 128 R 512 MIC
EURL ST.4,1 Trimethoprim, TMP R 4 S 0,5
EURL ST.4,2 Trimethoprim, TMP R 4 S 0,5
EURL ST.4,7 Trimethoprim, TMP R 4 S 0,5
40 EURL ST.4,4 Gentamicin, GEN R 6 S 0,25 DD
44 EURL ST.4,7 Penicillin, PEN R 0.5 S 0,06 MIC
13 DD
30 MIC
39 MIC
21 MIC
14 DD
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Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
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interpretation
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EURL EC.4,8 Cefotaxime, CTX S 0.12 R >4
EURL EC.4,8 Gentamicin, GEN S <0.25 R >16
4 EURL EC.4,6 Florphenicol, FFN R 16 S 16 MIC
11 EURL EC.4,6 Gentamicin, GEN R 4 S 4 MIC
EURL EC.4,4 Chloramphenicol, CHL R 18 S 8
EURL EC.4,6 Nalidixic acid, NAL R 14 S 16
EURL EC.4,7 Ciprofloxacin, CIP S 23 R 0,25
EURL EC.4,6 Florphenicol, FFN R 15 S 16
EURL EC.4,6 Nalidixic acid, NAL R 11 S 16
18 EURL EC.4,6 Florphenicol, FFN R 14 S 16 DD
EURL EC.4,7 Nalidixic acid, NAL S 64 R >64
EURL EC.4,8 Gentamicin, GEN S 1 R >16
EURL EC.4,7 Chloramphenicol, CHL R 32 S 4
EURL EC.4,7 Trimethoprim, TMP R >32 S 1
EURL EC.4,2 Tetracycline, TET R 2 S 2
EURL EC.4,3 Tetracycline, TET S <1 R >32
EURL EC.4,7 Ceftiofur, XNL S 21 R 8
EURL EC.4,8 Cefotaxime, CTX S <0.12 R >4
EURL EC.4,8 Ceftazidime, CAZ S <0.25 R 32
EURL EC.4,8 Gentamicin, GEN S <0.5 R >16
37 EURL EC.4,6 Streptomycin, STR S 16 R 32 MIC
EURL EC.4,1 Cefotaxime, CTX R 1 S 0,125
EURL EC.4,1 Ceftiofur, XNL R 16 S 0,5
EURL EC.4,1 Chloramphenicol, CHL S 2 R >64
EURL EC.4,1 Gentamicin, GEN R 4 S 1
EURL EC.4,1 Streptomycin, STR S <2 R 128
EURL EC.4,1 Sulfamethoxazole, SMX S 64 R >1024
EURL EC.4,1 Tetracycline, TET R 64 S 2
EURL EC.4,1 Trimethoprim, TMP R 32 S 1
EURL EC.4,3 Ceftiofur, XNL R 16 S 0,5
EURL EC.4,3 Florphenicol, FFN R >32 S 4
EURL EC.4,3 Tetracycline, TET S <0.5 R >32
EURL EC.4,3 Trimethoprim, TMP S 1 R >32
EURL EC.4,4 Ceftiofur, XNL R >16 S 0,5
EURL EC.4,4 Florphenicol, FFN R >32 S 8
EURL EC.4,4 Gentamicin, GEN R 4 S 0,5
EURL EC.4,4 Sulfamethoxazole, SMX S 64 R >1024
EURL EC.4,4 Tetracycline, TET S <0.5 R >32
EURL EC.4,5 Ceftiofur, XNL S 0.25 R >8
EURL EC.4,5 Chloramphenicol, CHL R >128 S 4
EURL EC.4,6 Ceftiofur, XNL R 4 S 0,5
EURL EC.4,6 Chloramphenicol, CHL S 4 R >64
EURL EC.4,6 Florphenicol, FFN R >32 S 16
EURL EC.4,6 Gentamicin, GEN R 16 S 4
EURL EC.4,7 Chloramphenicol, CHL R >128 S 4
EURL EC.4,7 Florphenicol, FFN R >32 S 4
EURL EC.4,7 Sulfamethoxazole, SMX S 64 R >1024
EURL EC.4,7 Tetracycline, TET S <0.5 R >32
EURL EC.4,8 Cefotaxime, CTX S 0.25 R >4
EURL EC.4,8 Chloramphenicol, CHL S 8 R >64
2 MIC
15 DD
21 MIC
19 MIC
14 DD
29 MIC
32 MIC
39 MIC
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EURL EC.4,2 Sulfamethoxazole, SMX R 6 S 64
EURL EC.4,4 Ciprofloxacin, CIP S 28 R 0,5
EURL EC.4,5 Ceftazidime, CAZ S 24 R 2
EURL EC.4,6 Ciprofloxacin, CIP S 22 R 0,5
EURL EC.4,7 Cefotaxime, CTX S 22 R >4
EURL EC.4,7 Ceftazidime, CAZ S 18 R 16
EURL EC.4,7 Ceftiofur, XNL S 17 R 8
EURL EC.4,7 Ciprofloxacin, CIP S 28 R 0,25
EURL EC.4,8 Ceftazidime, CAZ S 17 R 32
EURL EC.4,1 Cefotaxime, CTX R 2 S 0,125
EURL EC.4,1 Ceftazidime, CAZ R 1 S 0,25
EURL EC.4,5 Sulfamethoxazole, SMX R >1024 S 64
44 MIC
40 DD
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